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ABSTRACT 
Introduction:-Poor solubility of drug compounds which accounts for 40% of new molecules investigated at present is an issue of great concern 
in pharmaceutical industry and reducing particle size (i,e to reduce below 1000 nm )of drug candidate to be investigated is one of the simplest 
and efficient ways to overcome this challenge. Drug nanocrystals, solid nanosized drug particles are defined as formulation having 100% drug, 
which are covered by a stabilizer layer. In this study attempt was made to formulate and evaluate nanocrystals of poorly soluble drugs having 
low oral bioavailability. Material and method:- Nanocrystals were prepared successfully by varying concentration of different stabilizers by 
anti-solvent precipitation method. The formulated nanocrystals were evaluated by determining physicochemical characteristics such as 
physical appearance, Differential Scanning Calorimetry (DSC), scanning electron microscopy (SEM), X-ray powder diffractometry, solubility 
studies, particle size distribution, zeta potential, and in vitro drug release profile studies. Results:- An in-vitro study was performed on the 
successful formulation in comparison to drug powder using dissolution apparatus The particle size of RVT and PSNC-3 was found to be 1975.3 
nm and 790.1 nm respectively. Conclusion: Precipitated Nanocrystals formulated with different stablizer’s method resultedin formation of 
small and uniform RVT nanocrystals with an improved saturation solubility, dissolution rate.  
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1.0 INTRODUCTION  
Currently, poor solubility which is presently estimated for 
40% of new molecules investigated is  an issue of great 
concern  in drug discovery and  formulation development, to 
combat  the issue of poor aqueous solubility of hydrophilic 
drugs many techniques are explored viz  at molecular level 
prodrugs[1] , salt formation [2], co-solvent systems [3]or 
cyclodextrins [4] ,co-crystals [5], amorphous systems [6]or 
particle size reduction [7] have been studied widely. A 
another approach which can be explored for  enhancement 
of solubility as well as dissolution  are  documented as 
colloidal systems, like SEDDS/SMEDDS/SNEDDS[8] , 
(micro/nano)emulsions [9] or they may be different kinds of 
other lipid based systems like vesicular systems[10]. Based 
on the physicochemical characterization properties of the 
drug candidate, the most appropriate way to improve and 
enhance the solubility by above stated may be selected 
[11,12,13] Efficient screening methods explore number of  
poorly soluble drug molecules for pharmaceutical industry 
to commercialize , as it has been well documented that 
approximated ninety percent  of the new chemical entities 
are having poor aqueous solubility. According to 
Biopharmaceutics Classification System (BCS), these drug 
candidates or compounds are categorized as class II (70%) 
or class IV (20%) [14, 15] 
As classified in  BCS system, drugs  belonging to class II are 
well permeable but  poorly soluble, therefore are excellent  
& potential candidates to be formulated  as drug 
nanocrystals (NC )[16,17],  poorly soluble and poorly 
permeable drugs  which are categorized as BCS class IV as 
documented may be  benefited from decreased size [18,19]. 
For example, higher dissolution velocity resulted from 
higher and faster drug solubility a gradient on higher 
concentration side i develop between the intestine and 
lumen which consequently improved drug permeation and 
in turn improved bioavailability. Drug nanocrystals are drug 
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particles in nano range (i,e below 1000nm ), which are have 
sheath of stabilizer layer, are mostly exploited for enhancing 
the properties such as solubility of poorly soluble drugs [20] 
The main aim of current study is to enhance the dissolution 
rate, solubility as well as bioavailability of drug of the 
Rosuvastatin  (RVT), a poorly aqueous soluble drug by 
preparing nanocrystals using antisolvent precipitation 
technique. RVT crystalline nature can be considered as 
factor for reduction in aqueous solubility as well important 
parameter in reduction of oral bioavailability which is 
reported to be ≤ 20%. Rosuvastatin when administered 
orally, Cmax  (peak plasma Concentration) is reached within 
3–5 h, Vd (volume of distribution ) is 1.1-1.4 liter/Kg, and 
plasma protein binding is reported to be 90%. [21].  
2.0 MATERIAL AND METHODS  
 2.1 Materials.  Rosuvastatin calcium was gifted by 
Microlabs Pvt. Ltd.,Ethanol , Ploxomer-88, sodium Lauryl 
sulphate (SLS)were purchased from S.D. Fine Chemicals, 
Mumbai, India., , Span 80, Tween 80, Acetonitrile and 
Methanol were purchased from Sigma Aldrich, USA.  
Methods 2.2 
2.2.1. Ultraviolet Absorption Maxima (λmax) 
The 0.01% w/v solution (100µg/ml) of the Rosuvastatin 
Calcium in PBS (6.8), methanol, acetonitrile was scanned 
between 200-400nm and absorption maximum was 
determined spectrophotometrically (Systronic 2202, 
Ahmedabad, India). 
2.2.2 Solubility Studies 
Saturation solubility of pure drug Rosuvastatin as well as 
precipitated nanocrystals was estimated by method 
reported by Higuchi. Each sample in access amount was 
added to ten ml  of different media (0.1 N HCl), Phosphate 
Buffer (PBS) pH (6.8 and pH 7.4) in glass vials. These vials 
were then kept in orbital shaker for 48 h at 37°C. The 
solution was then filtered using syringe filter (0.22 μm), and 
the absorbance was taken using an ultraviolet (UV) 
spectrophotometer to determine the amount of drug 
dissolved.. 
 2.2.3 Formulation of nanocrystals 
Nanocrystals of RVT were prepared successfully using 
different polymeric stabilizers viz. Sodium Lauryl Sulphate , 
polaxmer 188 etc ,y antisolvent precipitation method. 100 
mg of pure drug was dissolved in 10 ml of Acetonitrile (ACN) 
(Solution I). Stabilizing agents were dissolved in 100 ml of 
double distilled water (Solution II). This Solution II was 
placed under propeller mixer at constant speed of 1400 rpm. 
Then, drug solution (Solution I) was injected into Solution II 
which is placed on magnetic stirrer with continuous stirring 
at 1000 rpm. Rotation per minute 500 was maintained 
overnight for complete removal of solvent. Once the organic 
solvent is removed the solution was then centrifuged at 
5000 rpm and supernatant solution so obtained was 
subjected to solidification by lyophilization by which water 
under vaccum  is removed from precipitated nanocrystals 
when it is in frozen state   (Allide Frost,New Delhi,India) at -
40°C for 24 hours to obtain the drug  nanocrystals. 
 
 
 
 
Table 1: Formulations with different ratios of drug: 
stabilizer 
Formulation 
code  
Stabilizer  Drug:Stabilizer 
ratio  
PNC-1 Polaxmer 188 1:1 
PNC-2  1:2 
PNC-3  1:3 
SNC-1 SLS 1:1 
SNC-2  1:2 
SNC-3  1:3 
PSNC-1 SLS: Polaxmer 188 1:1 
PSNC-2  1:2 
PSNC-3  1:3 
PNC= Polaxmer nanocrystals , SNC= Sodium lauryl sulphate 
nanocrystals, PSNC= Polaxmer Sodium lauryl sulphate 
nanocrystals 
 
2.2.4 Estimation of Particle Size Distribution and Zeta 
Potential (ZP) 
Zetasizer (Nano ZSTM Malvern Instruments, UK) was used for 
analysis of particle size and their distribution pattern of drug 
nanocrystals   using a process called dynamic light scattering 
(DLS). Parameters such as mean particle size, size 
distribution, and polydispersity index (PDI) were examined 
and determined. The particle size distribution (PSD) was 
characterized using PDI, which is a measure of the width of 
size distribution. Measurement of zeta potential of samples 
was performed by Zetasizer (Nano ZSTM Malvern 
Instruments, UK) using standard conductivity to avoid 
variation due to conductivity of H2O because in some 
instance drug candidate may contain electrolytes. The 
nanosuspension samples were measured in standard 
conductivity which was adjusted 1:1 (Distilled water) as well 
as original media in order to measure thickness of diffusion 
layer at 25°C for zeta potential and results were performed 
in triplicate. 
2.2.5 Crystalline state evaluation: 
 Powder X-Ray diffraction (PXRD) and Differential Scanning 
Colorimeter (DSC) techniques were used to evaluate the 
crystalline nature of Drug Nanocrystal formulations [22]. 
2.2.5.1 Differential Scanning Calorimetry (DSC):  
Differential Scanning Calorimeter Perkin-Elmer DSC-7 was 
used to evaluate thermal properties of the pure drug as well 
as precipitated drug nanocrystals.  It is well documented 
that amount of sample  to be  investigated and analyzed shall 
range between 4 to 7 mg and should be placed in crimped 
aluminum sealed 50 microliter pans.  Each sample subjected 
to analysis was exposed to heat runs which were   set 
between 50 to 300 degree Celsius maintained at  rate of 
scanning  10° min-1 so that quick redraw and image is 
available after display   , under dry nitrogen flow (100 
ml/min). 
2.2.5.2 Powder X-ray diffraction (PXRD):  
Diffractograms of every formulation and pure drug were 
observed recorded by technique PXRDusing (Philips 
analytical XRD PW3710) with radiation source used, having 
Cu line. Standard runs using forty kV voltage, a twenty five 
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mA current and a scanning rate of 1° min-1 over 2θ vary of 
10-70° were used 
2.2.6 Vesicles shape  
 Surface morphology of drug Nanocrystal formulation was 
examined at pH (7.4) and interpreted using scanning 
electron microscope (Jeol JSM-840A Japan). The sample to 
be analyzed were placed  on metal mount (Aluminum) and 
thus were cleaned,  and were coated with nine nm of gold / 
palladium  using a unit which is sputter-coated were 
recorded and  analyzed using SEM. 
2.2.7 In vitro drug release studies  
RVT Nanocrystal's release level was calculated using the 
(Basket type) type-I(United State Pharmacopeia)   
dissolution testing apparatus. The in vitro release profile 
(dissolution test) was conducted with a pH (1.2) buffer of 
900 ml at 37 ± 0.5ºC and 50 rpm. All formulations of drugs 
and pure drugs were individually filled in capsules and were 
subjected to dissolution study. A sample (5 ml) of the 
solution was collected from the dissolution system for 1 
hour after every 15 minutes interval having 0.1 N HCL as 
dissolution media containing sodium lauryl sulphate in 
concentration of   0.25% w/v, which was further followed by 
30 minutes interval for the next 5 hours. Absorbance of each 
solution was recorded against buffer solutions at 244nm 
using UV Spectrophotometer (Shimadzu's UV-1900i) and 
percentage drug release was calculated for each formulation. 
3.0 RESULT AND DISCUSSION  
3.1 Analytical method for the estimation of RVT using 
UV spectrophotometer 
The standard calibration plots of the drug were prepared in 
0.1 N hydrochloric acid solutions and phosphate buffer 
solution pH 6.8. The solutions of lornoxicam were scanned 
by the UV spectrophotometer at the wavelength range of 
800-400 nm.The λmax of drug solution is 244 nm in 0.1 N 
hydrochloric acid solutions and phosphate buffer solution 
pH (6.8, pH 7.4) 
3.2 Solubility Study 
RVT saturation solubility was performed for estimation in 
different buffer solutions to select appropriate dissolution 
medium for in vitro release studies. The saturation solubility 
of RVT in different media is shown in Table 3.  
Assessment of saturation solubility in distilled water, 0.1 N 
HCl (pH 1.2), phosphate buffer pH (6.8) & phosphate buffer 
pH (7.4) was carried out. An excess amount of rosuvastatin 
calcium (pure drug) and Nanocrystal formulation of drug 
were separately dispersed into 10 ml of medium in a conical 
flask. The mixture was stirred in orbital shaker incubator for 
24 hrs at a constant temperature of 37.0 ± 0.5 ºC. The 
sample was analyzed (after desired dilution) using UV 
spectrophotometer at 244 nm. The solubility data obtained 
for each formulation were calculated as an average of three 
measurements.  
In this study, kinetics of saturation solubility of rosuvastatin 
calcium (pure drug) and Nanocrystal formulation of drug 
were studied in the different dissolution media. The results 
of solubility study (Table 2) indicated increase in saturation 
solubility of Nanocrystal formulation of drug in the selected 
dissolution media. The Nanocrystal formulation of 
rosuvastatin calcium when compared with pure drug 
exhibited approximately three times and eight times 
increase in saturation solubility in distilled water and 0.1 N 
HCl respectively. This could be attributed to increase in 
surface area and the presence of pores/channels (as evident 
from SEM images) in the Nanocrystal formulation of 
rosuvastatin calcium. 
Table 2: Saturation solubility of rosuvastatin calcium 
and Nanocrystal formulation of rosuvastatin calcium 
Media RSV (mg/ml) PSNC-3(mg/ml) 
Distilled Water 3.77±0.85 9.51±1.67 
0.1 N HCl 0.63±0.21 4.09±1.09 
Phosphate buffer 
(6.8)  
1.08108 ±0.005  7.52±1.77 
Phosphate buffer 
pH(7.4) 
2.19107 ±0.0082 8.71±1.57 
 
3.3 Particle Size Distribution 
Particle size, polydispersity index (PDI) and zeta potential of 
rosuvastatin (RVT) and RVT formulated with different 
stabilizers as shown in (Table-3) were determined using 
Delsa NanoTM (Beckman Coulter, Germany) equipment. 
The particle size of RVT and PSNC-3 was found to be 1975.3 
nm and 790.1 nm respectively as shown in figure-1. The 
nanocrystals were characterized with respect to practical 
yield and particle size. The particle size and the width of the 
PSD are important characterization parameters as they 
govern in-vitro parameters such as saturation solubility, 
physical stability, drug dissolution and and in-vivo 
performance of nanoparticles. The PSD of PSNC-
3nanocrystals are shown in Table 2.. The results from clearly 
suggest that as drug: polymer ratio increased significant 
reduction in particle size of the drug could be correlated 
with the enhanced solubility/dissolution characteristics of 
nanocrystals of the drug. Nanoformulations offer the 
advantage of enhanced bioavailability at lower dosages, thus 
reducing side effects and hepatic load. Nanosized drug 
crystals provide a greater surface area for dissolution and 
increase the saturation solubility, ultimately increasing 
dissolution, which leads to enhanced absorption in vivo. 
Commercial concerns relate to safety, because this affects 
regulatory approvals. The term ‘nano’ by itself is too wide 
and in the context of nanoformulations, there has to be 
correctly defined ‘range’ which is considered ‘safe’ for 
approval, from a regulatory perspective. Transport of 
nanocarriers into lymphatic vessels is dependent on particle 
size. Nano carrier size lies between 200-800 nm to avoid 
uptake by the reticulo-endothelial system. Oussoren et al[23] 
reported that a particle size of 10–100 nm is optimal for 
lymphatic uptake. The mean particle for different 
formulations available lies between 300 -800nm. As 
physicochemical properties of drugs vary, therefore there is 
a need for the size to be optimized for different API’S. In case 
of present formulation, the particle size is about 700 nm i.e. 
well within the safe limit. 
The PDI and zeta potential results indicated that lyophilized 
nanocrystal formulation was physically stable.   
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Table 3: Particle size, polydispersity index (PDI) and zeta potential of rosuvastatin (RSV) and various Nanocrystal 
formulations 
Formulation 
code  
Stabilizer  
 
Drug:Stabilizer 
ratio  
Particle 
size(nm) 
Zeta Potential 
(mV) 
PDI 
Pure Drug   1975.3 -14.61 0.790 
PNC-1 Polaxmer 188 1:1 1073.2 -18.56 0.856 
PNC-2  1:2 1123.1 -17.75 0.968 
PNC-3  1:3 934 -15.61 0.798 
SNC-1 SLS 1:1 1235 -14.63 0.545 
SNC-2  1:2 1345 -19.61 0.654 
SNC-3  1:3 956 -9.69 0.786 
PSNC-1 SLS: Polaxmer 188 1:1 956 -14.61 0.445 
PSNC-2  1:2 863.2 -10.26 0.346 
PSNC-3  1:3 790.2 -14.61 675 
PNC= Polaxmer nanocrystals , SNC= Sodium lauryl sulphate nanocrystals, PSNC= Polaxmer Sodium lauryl sulphate nanocrystals 
 
 
Figure 1 Particle size distribution of pure drug and Drug  nanocrystals 
 
3.4 Differential scanning calorimetry (DSC): 
It is well documented that  DSC i,e Differential Scanning 
Calorimetry, is explored to analyze and forecast changes in 
drug's crystallinity. Polymorphism may interpret as    
substance’s ability as well tendency to exist in one or more 
crystalline forms.  Alterations in melting point, variation in 
bioavailability and drug release are expected due to change 
in drugs polymorphic nature. Due to its phase transition, a 
characteristic large and sharp peak was observed at 175.19 °  
for  Rosuvastatin Calcium At 171.44 ° and 180.59 ° 
respectively, the start and end of the RVT phase transition 
array are observed. DSC formulation thermogram, PSNC-1 
showed an endothermic peak at 173.92 ° C which may be 
lead to interpret as a slight change in crystalline nature. 
Formulations [A] (PSNC-2, [B] (PSNC-3) having composition 
as shown in (Table 3), DSC thermograms displayed  small but  
sharp characteristic  endothermic peak at 174.87 ° and 
174.57 respectively. Based on results obtained and 
interpretation of  DSC thermogram of formulation which may  
be considered for further studies  displayed characteristic 
endothermic peaks corresponding to those of the pure drug, 
and one or more new peaks or disappearances 
corresponding to those of the pure drug do not occur.
 
  
Fig:2  DSC Patterns of pure RVT (A) ,(B) PSNC-2 ,(B) PSNC-3. 
 
A B C 
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3.5 XRD Analysis 
XRD measurement was performed by X-ray diffractometer 
(Bruker, Germany) over the range of angle 2-theta of 5º to 
40º with a step width of 0.04º and a count time of 4 s. An 
amorphous form of a compound intended for 
pharmaceutical use may give rise to manufacturing 
problems and there is need to identify crystalline forms of 
these compounds which may have different physical 
characteristics compared to amorphous form. Crystalline 
forms of such compounds may also possess improved 
physical, chemical and pharmacological characters such as 
improved solubility/dissolution, enhanced bioavailability 
etc. XRD spectra of PSNC-3 clearly indicate the presence of 
additional sharp peaks. Moreover, splitting of peak 
(specifically near to 2θ value of 20) could be seen in PSNC-3 
when compared with RSV. It point out towards the increase 
in crystalline behavior of PSNC-3 as compared to RVT. 
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Counts
0
500
1000
 PD
 
(A) 
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Figure 3: XRD spectra of (A) rosuvastatin calcium (B) PSNC-3 
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Table 4: XRD analysis parameters (2θ, d spacing, relative intensity) of rosuvastatin calcium (RSV) and Nanocrystal 
formulation of rosuvastatin calcium (PSNC-3). 
RSV 
S. No. 2θ d spacing Relative Intensity 
1. 9.03 9.78 21.14 
2. 20.23 4.38 100 
PSNC-3 
1. 5.53 15.95 8.05 
2. 7.04 12.53 100 
3. 7.99 11.05 15.97 
4. 20.56 4.31 59.96 
5. 20.85 4.25 62.89 
6. 22.01 4.03 45.55 
7. 23.21 3082 25.99 
8. 30.69 2.91 14.68 
9. 32.35 2.76 12.64 
 
3.6 Scanning Electron Microscopy (SEM Analysis) 
The morphological characteristics of rosuvastatin calcium 
and Nanocrystal formulation of rosuvastatin calcium were 
examined using scanning electron microscope. 
SEM images of pure RVT indicates compact and discrete 
surface. However, SEM images of PSNC-3 shows the presence 
of channels and pores. Increased surface area could also be 
seen in the images. 
 
 
Figure 4: Scanning electron microscopy images of pure drug (A&B) and PSNC-3 (C&D) 
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3.7 In vitro drug release studies 
The in vitro dissolution of rosuvastatin calcium and 
Nanocrystal formulation of rosuvastatin calcium from tablet 
and capsule formulation was determined using USP 
Apparatus 2 dissolution tester (Labindia, Mumbai, India). 
The dissolution test was conducted in 0.1 N HCl 900 ml. The 
speed of the paddle was 50 rpm. Holding the temperature at 
37 ± 0.5ºC also at the predetermined time points, five 
milliliters of dissolution medium is obtained from the vessel. 
The collected sample was immediately filtered through a 
membrane filter of 0.2μm and fresh dissolution media were 
replenished into the vessel immediately. The samples were 
using UV spectrophotometer at 244 nm. For each sample, 
three replicate dissolution tests were performed.  
The drug release (after 15 minutes) from tablet formulation 
of RVT and PSNC-3 (optimized formulation) was nearly 12% 
and 32% respectively. After 60 minutes the drug release was 
found to be 41% and 83% from tablet formulation of RSV 
and PSNC-3 respectively. In case of capsule formulation of 
RSV and PSNC-3, the drug release was found to be 
approximately 10% and 40% respectively after 15 minutes. 
After 60 minutes the drug release was found to be 41% and 
83% from capsule formulation of RSV and PSNC-3 
respectively. The results suggested that the PSNC-3 had a 
significant effect on the drug solubility, dissolution rate, and 
dissolution behavior. 
 
 
Figure 5:- In vitro dissolution profile of rosuvastatin calcium and Nanocrystal formulation with different stabilizers in 
different media 
 
Figure 5:  In vitro dissolution profile of rosuvastatin calcium and PSNC-3 tablets 
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Figure 6:  In vitro dissolution profile of rosuvastatin calcium and PSNC-3 capsules 
 
4.0 CONCLUSION 
Rosuvastatin calcium is an Anti-hyperliperdemic drug of the 
statin class with analgesic belongs to BCS Class IV Therefore; 
an attempt has been made to improve solubility by 
converting pure drug of RVT m which is in micronized form 
to nanosized form. Nanocrystals of RVT were developed 
with different ratios of SLS, polaxmer 188, by antisolvent 
precipitation method. The FTIR spectroscopy was used to 
confirm compatibility and to rule out any possible 
interactions between drug and polymers. Nine nanocrystal 
formulations (SNC-1,SNC-2) SNC-3,PNC-1, PNC-2, PNC-
3,SPNC-1,SPNC-2,SPNC,3) consisting pure drug of RVT 
(micronized form) with SLS, polaxmer 188 used as 
stabilizers in the ratios of 1:1, 1:2, and 1:3, respectively,  
All formulations carried using acetonitrile and double 
distilled water as antisolvent system. The prepared 
nanocrystals were evaluated for their physicochemical 
characteristics such as physical appearance, FTIR, DSC, SEM, 
XRD, solubility studies, PSD, zeta potential, and in vitro drug 
release studies. In vitro drug release from nanocrystals was 
carried out in different buffers, and the data obtained were 
fit into different equations and kinetic models to explain 
release kinetics.  Rosuvastatin with SLS, polaxmer 188 in 1:3 
ratio formulations in 0.1 N Hcl & 7.4 pH phosphate buffer  
and showed better solubility and emerged to be ideal 
formulation for Rosuvastatin calcium nanocrystals. Hence, it 
can be concluded that optimized nanocrystals formulation of 
RVT improved the solubility and dissolution of Rosuvastain 
calcium as compared to pure drug. 
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